
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Remove Advisory bodies/Committees filter Advisory bodies/Committees (1)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Complementary medicines (7) Apply Complementary medicines filter
- Remove Cosmetics filter Cosmetics (0)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Remove Prescription medicines filter Prescription medicines (6)
- Scheduling (85) Apply Scheduling filter
- Sunscreens (1) Apply Sunscreens filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Prescription medicines filter Prescription medicines
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Advisory bodies/Committees filter Advisory bodies/Committees
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Cosmetics filter Cosmetics
Adoption of International Scientific Guidelines in Australia
Closed on 20 February 2022
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Building a more robust medicine supply - proposals to help prevent, mitigate and manage medicine shortages
Closed on 17 May 2021
Repurposing of prescription medicines
Closed on 30 March 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
Boxed Warning guidance
Closed on 31 August 2018